Deciphera's Qinlock Fails Phase 3 Trial in Second-Line GIST, Shares Plummet 75%
核心洞察
Deciphera Pharmaceuticals (搜索)' Qinlock failed to outperform Pfizer's Sutent in second-line gastrointestinal stromal tumor (搜索) treatment, with progression-free survival of 8.0 versus 8.3 months respectively.
The disappointing INTRIGUE trial results severely impact Qinlock's projected blockbuster potential, previously estimated at $1.5 billion in annual sales.
Currently approved as a fourth-line therapy, Qinlock generates modest quarterly sales of around $20 million, with a pending European approval offering limited upside potential.
Deciphera Pharmaceuticals (搜索) faced a significant setback as their KIT (搜索) inhibitor Qinlock (ripretinib) failed to demonstrate superiority over standard therapy in a crucial phase 3 trial, sending the company's shares plunging 75% on Friday.
The INTRIGUE study evaluated Qinlock as a second-line treatment for gastrointestinal stromal tumor (搜索) (GIST) patients who had received prior imatinib therapy. The trial results showed Qinlock achieved a progression-free survival of 8.0 months, compared to 8.3 months with Pfizer's Sutent (sunitinib), failing to meet its primary endpoint. While a subgroup of patients with exon 11 KIT (搜索) mutations showed a modest trend favoring Qinlock, the difference did not reach statistical significance.
Current Market Position and Future Implications
Qinlock currently holds FDA approval as a fourth-line therapy for GIST in adults who have undergone treatment with three or more kinase inhibitor therapies, including imatinib. The drug's approval last year came after the FDA's rejection of Blueprint Medicines' competing therapy Ayvakit (avapritinib), initially positioning Qinlock favorably in the market.
However, the drug's commercial performance has been modest, with quarterly sales hovering around $20 million. While an anticipated European approval for fourth-line GIST treatment may provide some additional revenue, analysts suggest this represents close to the maximum US sales potential under the current label.
Company Response and Strategic Review
"We are surprised and disappointed by these results," stated Steve Hoerter, Deciphera's CEO, during an investor conference call. He emphasized that the trial was "robust, well-designed, and well-executed," despite the unexpected outcome.
In response to this setback, Deciphera has initiated a portfolio review to evaluate potential future directions for Qinlock in GIST treatment. The company maintains a pipeline of other developmental candidates, including:
- Vimseltinib, a CSF1R inhibitor preparing for phase 1/2 trials in tenosynovial giant cell tumor
- Rebastinib, a TIE2 inhibitor being studied in combination with paclitaxel for solid tumors
- DCC-3116, a ULK inhibitor in development for RAS/RAF mutant cancers
Market Impact and European Prospects
The trial failure has effectively dampened previous analyst predictions of Qinlock achieving annual sales exceeding $1.5 billion. While the European market presents an opportunity with a patient population comparable to the US, post-approval pricing negotiations make revenue projections uncertain.
The dramatic 75% decline in Deciphera's stock price reflects the market's reassessment of Qinlock's commercial potential, particularly given the lost opportunity to expand into earlier lines of GIST treatment.